Cancer antigen 19-9

This test uses Roche CA 19-9 electrochemiluminescent immunoassay. Results obtained with different test methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. CA 19-9 value regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease. CPT Codes The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.

High levels of certain tumor markers in the blood can indicate the presence of Also known as biomarkers, these substances can be measured using a blood test. But having a high level of one of these tumor markers doesn’t necessarily mean you have ovarian cancer. Doctors don’t use tumor marker blood tests to screen people at average risk of ovarian cancer. But they are helpful in assessing Read on to learn about various ovarian cancer tumor markers and how they’re used. There are a number of different types of ovarian tumor marker tests. Each test looks for a different kind of biomarker. CA-125 The However, some benign, or noncancerous, conditions can also lead to elevated CA-125. These include: • • • HE4 Human epididymis protein 4 (HE4) is another tumor marker. It’s often overexpressed in epithelial ovarian cancer cells, which are cells in the outer layer of the ovary. Small amounts of HE4 can also be found in the blood of people without ovarian cancer. This test may be used in conjunction with a CA-125 test. CA19-9 Cancer antigen 19-9 (CA19-9) is elevated in several types of cancer, including pancreatic cancer. Less often, it’s due to ovarian cancer. It can also indicate a benign ovarian tumor or another benign disease. You can also be healthy and still have small amounts of CA19-9 in your blood. This test isn’t typically used to look for ovarian cancer. In a CA72-4 Several types of gastrointestinal and gynecological cancers are associated with high levels of cancer antige...

(1 2 S,1 4 S,1 5 R,1 6 R,3 2 R,3 3 R,3 4 S,3 5 S,3 6 R,5 2 R,5 3 S,5 4 R,5 5 R,5 6 Ξ,7 2 S,7 3 S,7 4 R,7 5 S,7 6 S)-1 5,5 5-Diacetamido-1 4,3 3,3 5,5 6,7 3,7 4,7 5-heptahydroxy-3 6,5 2-bis(hydroxymethyl)-7 6-methyl-1 6-[(1 R,2 R)-1,2,3-trihydroxypropyl]-2,4,6-trioxa-1,7(2),3(4,2),5(4,3)-tetraoxanaheptaphane-1 2-carboxylic acid Other names Chemical compound Carbohydrate antigen 19-9 ( CA19-9), also known as sialyl-Lewis A, is a Structure [ ] CA19-9 is the sialylated form of A. It is a Clinical significance [ ] Tumor marker [ ] Guidelines from the In people with Limitations [ ] CA19-9 can be elevated in many types of gastrointestinal cancer, such as In patients who lack the History [ ] CA19-9 was discovered in the serum of patients with See also [ ] • • References [ ] • ^ a b c d e Perkins, G.; Slater, E.; Sanders, G.; Prichard, J. (2003). American Family Physician. 68 (6): 1075–1082. • ^ a b c Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006). J. Clin. Oncol. 24 (33): 5313–27. • ^ a b c d Goonetilleke KS, Siriwardena AK (April 2007). "Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer". Eur J Surg Oncol. 33 (3): 266–70. • Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981). "Specific antigen in serum of patients with colon carcinoma". Science. 212 (4490): 53–5. • Magnani, JL (15 June 2004). "The discovery, biology, and drug development of sialyl Lea and sialyl ...

Endoscopic retrograde cholangiopancreatography Endoscopic retrograde cholangiopancreatography (ERCP) uses a dye to highlight the bile ducts and pancreatic duct on X-ray images. A thin, flexible tube (endoscope) with a camera on the end is passed down your throat and into your small intestine. The dye enters the ducts through a small hollow tube (catheter) passed through the endoscope. Endoscopic ultrasound During an endoscopic ultrasound, your doctor inserts a long, flexible tube (endoscope) down your throat and into your abdomen. An ultrasound device at the end of the tube emits sound waves that generate images of nearby tissues. If your doctor suspects cholangiocarcinoma, he or she may have you undergo one or more of the following tests: • Liver function tests. Blood tests to measure your liver function can give your doctor clues about what's causing your signs and symptoms. • Tumor marker test. Checking the level of carbohydrate antigen (CA) 19-9 in your blood may give your doctor additional clues about your diagnosis. CA 19-9 is a protein that's overproduced by bile duct cancer cells. A high level of CA 19-9 in your blood doesn't mean you have bile duct cancer, though. This result can also occur in other bile duct diseases, such as bile duct inflammation and obstruction. • A test to examine your bile duct with a small camera. During endoscopic retrograde cholangiopancreatography (ERCP), a thin, flexible tube equipped with a tiny camera is passed down your throat and th...

What is this test? This test looks for the antigen called cancer antigen 19-9 (CA 19-9) in your blood. Antigens are substances that stimulate your body's immune system. Some types of cancer cells send CA 19-9 into the blood, where it can be measured with this test. A high amount of CA 19-9 is most often caused by pancreatic cancer. But it can also be caused by other types of cancer. And it can be caused by infections in your liver, gallbladder, and pancreas. Antigens like CA 19-9 that give information about cancer are called tumor markers. This test is not used as a screening test for cancer. Why do I need this test? You may need this test if your healthcare provider thinks you might be at risk for cancer. This may be because of your symptoms or because you have a family history of cancer. You may need this test as part of your diagnosis along with other tests. You may also need this test if you are having cancer treatment. It may be done every week or so to see how well treatment is working. You may also need this test if you have already been treated for cancer and your healthcare provider wants to see if your cancer has come back. This test works best to help diagnose or make decisions about treatment for pancreatic cancer. But it may also be used for other cancers. What other tests might I have along with this test? Your healthcare provider may also order tests to check for other tumor markers. You may have imaging scans or other blood tests to learn about your cancer....

Medical providers will order the CA 19-9 blood test to use as a tumor marker. It is not a sensitive enough blood test to be able to use it as a screening tool to diagnose a malignancy, but it can help to differentiate whether there is a cancer present or an inflammation or infection that is causing bothersome symptoms. It is also ordered to monitor how an individual is responding to medical treatments and can be used to watch for a relapse of a cancer. It is an effective blood test only when a tumor is creating enough of this marker, so it is typically ordered with a series of other tests that measure the functioning of the liver and pancreas. About 6 in 10 people with bile duct cancer will also have elevated levels of CA 19-9, so it may also be ordered if this condition is suspected. CA 19-9 levels may also rise if there is a bile duct obstruction. When Should I See a Doctor? Unfortunately many of the conditions that the CA 19-9 blood test is able to detect have a cause that is currently unknown to medical science. There are certain risk factors that may indicate a higher than normal risk for developing pancreatic cancer. These include being in the 50+ age demographic, being male, having diabetes, or having a family history of pancreatic or similar cancers. Individuals who have be exposed to certain dyes and chemicals also have an increased risk of cancer development. About 80% of people who do have pancreatic cancer will experience some level of abdominal pain. This is d...